Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer.

Trial Profile

Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs SAR 566658 (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 31 Jul 2019 to 2 Aug 2019.
    • 13 Jul 2017 Planned primary completion date changed from 31 Jul 2019 to 2 Aug 2019.
    • 14 Mar 2017 Planned End Date changed from 28 Jun 2019 to 31 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top